A carregar...
Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey
Access to bevacizumab, an important component of oncology treatment regimens, may be limited. This survey of oncologists in the US (n = 150), Europe (n = 230), and emerging markets (EM: Brazil, Mexico, and Turkey; n = 130) examined use of and barriers to accessing bevacizumab as treatment of advance...
Na minha lista:
| Publicado no: | Pharmaceuticals (Basel) |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5374423/ https://ncbi.nlm.nih.gov/pubmed/28134851 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph10010019 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|